The DOI matches its Crossref record; 336 of the 343 references it cites were found in a registry or an index.
Nanotechnology-based drug delivery for breast cancer treatment: Current applications and future directions
Open accessAbstract
Breast cancer (BC) is one of the most prevalent cancers in women worldwide. Limited specificity, systemic toxicity, risk of recurrence, and drug resistance are some of the drawbacks of traditional BC treatment approaches. Therefore, it is crucial to develop more effective, safe, and customized management plans for BC. The application of nanoparticle-based systems, such as liposomes, nanostructured lipid carriers, polymeric micelles, polymeric nanoparticles, dendrimers, and hybrid nanoparticles, has drawn significant interest in BC treatment. Nanomedicine can enhance the efficacy of drugs through active targeting, better tissue penetration, and more efficient tumor suppression via improved retention and permeability. Additionally, gene delivery using hybrid and theranostic nanomedicine has also been explored in BC treatment. Numerous nanomedicines have been used clinically for the treatment of breast cancer, some of which have already received U.S. Food and Drug Administration (USFDA) approval. Here, we focus on nanotechnology-based therapeutic approaches for BC treatment and highlighted their enhanced efficacy and reduced side effects. In addition, we have also explored on the possible utilization of Artificial Intelligence (AI) nanomedicine and bioinspired nanocarriers for BC treatment, which could pave the way for more precise, effective, and personalized therapies by improving nanoparticle design, optimizing drug delivery systems, and leveraging big data analytics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The route of administration also remains a practical limitation, as intratumoral delivery may not be feasible for all anatomical sites, whereas systemic administration raises concerns regarding off-target accumulation and toxicity [25,97].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]
In the citing paper
“Many preclinical studies rely on passive targeting through the enhanced permeability and retention (EPR) effect, which is highly variable and generally less pronounced in human tumors than in experimental models [5,97].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]
In the citing paper
“These systems established the proof-of-concept that nanomaterials could enhance radiation-induced damage, but they also highlighted important limitations related to tumor hypoxia, antioxidant defenses, heterogeneous intratumoral distribution, and variable nanoparticle accumulation [11,12,25,95,97].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]
In the citing paper
“Although these combinatorial systems often demonstrate enhanced efficacy experimentally, their clinical development is challenged by issues related to reproducibility, manufacturing consistency, regulatory approval, scalability, and long-term safety [25,96,97].”
From Nanoparticle-Mediated Radiosensitization in Breast Cancer: A Systematic Review of Preclinical Evidence and Translational Challenges (2026) · cites this paper as [97]
Citations
Cites
Polymeric Nanoparticles: Production, Characterization, Toxicology and Ecotoxicology
Zielińska, A., Carreiró, F., Oliveira, A. M., Neves, A., Pires, B., Venkatesh, D. N., Durazzo, A., Lucarini, M., Eder, P., Silva, A. M., et al. (2020) · Molecules · doi:10.3390/molecules25163731 · Cited by 1,560
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Polymeric Nanoparticles for Drug Delivery
Beach, M. A., Nayanathara, U., Gao, Y., Zhang, C., Xiong, Y., Wang, Y., & Such, G. K. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00705 · Cited by 1,279
A Comparative Review of Natural and Synthetic Biopolymer Composite Scaffolds
Reddy, M. S. B., Ponnamma, D., Choudhary, R., & Sadasivuni, K. K. (2021) · Polymers · doi:10.3390/polym13071105 · Cited by 1,104
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Wu, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080771 · Cited by 1,030
Mohammadi‐Samani, S., & Ghasemiyeh, P. (2018) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.235156 · Cited by 975
Effects of polyethylene glycol on the surface of nanoparticles for targeted drug delivery
Shi, L., Zhang, J., Zhao, M., Tang, S., Xu, C., Zhang, W., Li, W., Liu, X., Peng, H., & Wang, Q. (2021) · Nanoscale · doi:10.1039/d1nr02065j · Cited by 843
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature)
Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022) · Cancers · doi:10.3390/cancers14102569 · Cited by 699
Research works printed but not linked: 10
- Arshad, 2022, Nano-based theranostic platforms for breast cancer: a review of latest advancements, Bioeng. (Basel, Switzerland), 9
- Viegas, 2023, Solid lipid nanoparticles vs. Nanostructured lipid carriers: a comparative review, Pharm. Times, 15, 1593
- Madej, 2022, Polymeric nanoparticles—tools in a drug delivery system in selected cancer therapies, Appl. Sci., 12, 9479, 10.3390/app12199479 · DOI
- Arshad, 2022, Nano-based theranostic platforms for breast cancer: a review of latest advancements, Bioeng, 9, 320
- Qureshi, 2024, “Revolutionizing breast cancer care: cutting-edge breakthroughs and, Future Frontiers in Precision Medicine,”, 115
- Chiara, 2022, “2021-WORLD journal of medical innovations, Available at,” WJMI, 1
- Sadr, 2024, Gold nanobiosensors and Machine Learning: pioneering breakthroughs in precision breast cancer detection, Eur. J. Med. Chem. Reports, 12
- Bolla, 2024, Challenges and opportunities in the development of nanoparticle systems for cancer drug delivery, J Recent Adv Nanomed Nanotech, 1
- Hari, 2022, Polymeric micelles and cancer therapy: an ingenious multimodal tumor-targeted drug delivery system, Drug Deliv. Transl. Res., 13, 135, 10.1007/s13346-022-01197-4 · DOI
- Bachhav, 2020, vol. 7
Cited by
Sorted by citations
Breast Cancer: Molecular Pathogenesis and Targeted Therapy
Samad, M. A., Ahmad, I., Khan, M. R., Suhail, M., Zughaibi, T. A., Al-Abbasi, F. A., Alhosaini, K. A., Khan, M. S., Kumer, A., & Tabrez, S. S. M. (2025) · MedComm · doi:10.1002/mco2.70404 · Cited by 28
Self-citationKrishnan, A., & Francis, M. A. (2025) · BioNanoScience · doi:10.1007/s12668-025-02237-2 · Cited by 12
Natural-Based Magnetite/Hydroxyapatite/Chitosan Nanocomposite as Effective Drug Delivery Systems
Utami, R., Habani, M. H., Sunaryono, S., Munasir, M., Sani, N. S., Yustanti, E., Tahir, D., & Taufiq, A. (2025) · Journal of Cluster Science · doi:10.1007/s10876-025-02861-8 · Cited by 9
Radiopaque Silk Sericin Nanoparticles for Computed Tomography Imaging of Solid Tumors
Bhoopathy, J., Vedakumari, S. W., Pravin, Y. R., & Prabhu, A. D. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00230 · Cited by 8
Aneja, P., Guleria, R., & Dahiya, D. P. (2025) · Assay and Drug Development Technologies · doi:10.1089/adt.2025.026 · Cited by 6
Metadata
- Authors
- Samad, M. A., Ahmad, I., Zughaibi, T. A., Suhail, M., Zaidi, S. K., Al-Abbasi, F. A., & Tabrez, S.
- Affiliations
- King Abdulaziz University (SA)
- Corresponding author
- Tabrez, Shams
- ORCID
- Venue
- European Journal of Medicinal Chemistry Reports
- Publisher
- Elsevier BV
- Published
- 2025-08
- Volume
- 14
- Pages
- 100268
- ISSN
- 2772-4174 (ISSN-L)
- OpenAlex
- W4409392096
- Cited by
- 35
- References
- 343
- Citations by year
- 2026: 21 · 2025: 14
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- European Journal of Medicinal Chemistry Reports (publishedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- King Fahad Medical City
- King Abdulaziz University
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- breast cancer, nanomedicine, drug delivery systems, liposomes, nanostructured lipid carriers, polymeric micelles, polymeric nanoparticles, dendrimers, hybrid nanostructures, nanotheranostics, gene delivery, targeted drug delivery, drug resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
